Japan Tobacco and D-Wave Announce Quantum Proof-of-Concept Outperforms Classical Results for LLM Training in Drug Discovery
Japan Tobacco and D-Wave Announce Quantum Proof-of-Concept Outperforms Classical Results for LLM Training in Drug Discovery
D-Wave Quantum Inc. (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) today announced the completion of a joint proof-of-concept project that used quantum computing technology and artificial intelligence (AI) in the drug discovery process. JT and D-Wave enhanced large language models (LLMs) with a quantum-hybrid workflow to increase their generative capabilities and enable JT to produce novel, more ‘drug-like’ molecular structures beyond those found in the training datasets for the quantum-hybrid generative AI system.